A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit

Mutations in IDH1 are highly prevalent in human glioma. First line treatment is radiotherapy, which many patients often forego to avoid treatment-associated morbidities. The high prevalence of IDH1 mutations in glioma highlights the need for brain-penetrant IDH1 mutant-selective inhibitors as an alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopinja, Johnny, Sevilla, Raquel S., Levitan, Diane, Dai, David, Vanko, Amy, Spooner, Edward, Ware, Chris, Forget, Robert, Hu, Kun, Kral, Astrid, Spacciapoli, Peter, Kennan, Richard, Jayaraman, Lata, Pucci, Vincenzo, Perera, Samanthi, Zhang, Weisheng, Fischer, Christian, Lam, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653818/
https://www.ncbi.nlm.nih.gov/pubmed/29062039
http://dx.doi.org/10.1038/s41598-017-14065-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653818/
https://www.ncbi.nlm.nih.gov/pubmed/29062039
http://dx.doi.org/10.1038/s41598-017-14065-w

Ejemplares similares